BioWorld

Radiopharma Clarity touts advantages of its targeted copper theranostics

Clarity Pharmaceuticals Ltd. is progressing three of its targeted copper theranostics through the clinic that are based on its sarcophagine technology that securely holds copper isotopes inside a cage ...
Pharmabiz

Clarity Pharma begin patient dosing in phase III prostate cancer trial with Cu-64 SAR-bisPSMA

Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company, announce that the first patient has been dosed in its pivotal phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, ...
Kosmo

Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

SYDNEY, Feb. 16, 2026 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that ...
Seeking Alpha

SABRE topline results: Cu-64 SAR-Bombesin is effective in detecting prostate cancer recurrence in patients with negative SOC imaging

SYDNEY, June 13, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that ...
Mena FN

Clarity Receives FDA Fast Track Designation For 64Cu-SAR-Bispsma

(MENAFN- PR Newswire) SYDNEY, Aug. 22, 2024 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation ...
WRIC

Positive guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III trial in patients with recurrence of prostate cancer

SYDNEY, Oct. 14, 2024 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products ...
Yahoo Finance

Clarity enters a Commercial Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx

Clarity has entered into a Commercial Manufacturing Agreement with SpectronRx for 64 Cu-SAR-bisPSMA. SpectronRx's facility in Indiana will provide on-demand commercial-scale manufacturing of both ...
KHON2

Clarity's US-based Cu-64 SAR-bisPSMA trial in prostate cancer opens for recruitment

SYDNEY, March 28, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in ...
manilatimes

Clarity signs a large-scale Manufacturing Supply Agreement for copper-64 with Theragenics

SYDNEY, March 25, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that ...